Enzymatic Determination of Lipoprotein-X, a Specific Serum Cholestasis Marker by Talafant, E. & Továrek, J.
Talafant and Tov rek: Enzymatic determination of lipoprotein-X 155
J. Clin. Chem. Clin. Biochem.
Vol. 19, 1981, pp. 155-157
Enzymatic Determination of Lipoprotein-X, a Specific Serum Cholestasis Marker
By£ Talafant and J. Tovarek
Department of Medical Chemistry and Biochemistry, and Third Medical Clinic, Faculty of Medicine,
University J. E. PurkynS, Brno, Czechoslovakia
(Received June 24/November 3, 1980)
Summary: Non-esterified cholesterol was determined enzymatically with the cholesterol oxidase-peroxidase
reaction using phenol and 4-aminophenazone as chromogens. This assay was done in the supernatant containing
the lipoprotein-X. Other serum lipoproteins were removed by precipitation with heparin and zinc acetate followed
by centrifugation. No standardization was required, the lipoprotein-X concentration being calculated with the use of
the constant.
Enzymatische Bestimmung des fur Cholestase charakteristischen Lipoprotein-X im Serum
Zusammenfassung: Das unveresterte Cholesterin wurde enzymatisch mit der Cholesterinoxidase-Peroxidase Reak-
tion unter Verwendung von Phenol und 4-Aminophenazon als Chromogene bestimmt. Der Test wurde im berstand
durchgef hrt, welcher das Lipoprotein-X enthielt, nachdem andere Lipoproteine durch F llung mit Heparin und
Zink cetat und nachfolgende Zentrifugation entfernt worden waren. Keine Standardisierung war notwendig, da die
LipoproteinOC-Konzentration mittels der Konstante berechnet wurde.
Introduction
Lipoprotein-X, a specific marker of cholestasis, was
hitherto determined by rather complicated procedures.
Its quantitative determination may be helpful, e. g. for
differentiating between the intra- and extrahepatic cho-
lestasis in infants receiving cholestyramine, (Campbell,
D. P. & Williams, R. G., cf. in 1. c. (1)). The turbidimetric
method ofGoverde et al. (2) utilizes antiserum to remove
the interacting lipoproteins. The turbidimetric method
without antibody described in the previous paper (3)
suffers from the general disadvantages of measuring
turbidity. It requires standardization with lipoprotein-X
solution of a known concentration. The preparation of
lipoprotein-X concentrate, although much simplified
(3), includes collecting strongly lipoproteinOC positive
sera s its source. These complications have been over-
come by measuring npnresterified cholesterol by the
specific enzymatic test (4). The non*esterified chole-
sterol represents one of the major lipoprotein-X con-
stituents (224 g/kg) (Seidel, D., et al., cf. in 1. e. (1)).
The lipoprotein-X consists of the subfractions lipopro-
tein-Xj, lipQprptein-X2 and lipoprotein-X3, the chol-
esterol contents of which differ slightly (Patsch, J. R.
et al., of. in 1. c. (1)); This does not affect seriously the
lipoprotein-X determinations based on its cholesterol
content. The lipoproteins other than lippprotein-X were
removed from the examined serum using the prnciple
devised by Sobeslavsky and modified in the method
previously described (3).
Materials and Methods
Spekol 10 (Carl Zeiss, Jena GDR) with plastic cuvettes (Sar-
stedt, Numbrecht-Rommelsdorf, FRG), light path 1 cm, width
0.4 cm, height 3.1 cm (cut from the original height of 4.5 cm)
were used for measurements. From the commercial kit "Chol-
esterin, Boehringer Mannheim CHOD-PAP Methode, No. 172626"
only the solutions 1 and 2 (the chromogens) were used to prepare
the reagent: 1 volume of the solution 1 with 1 volume of the
solution 2 were mixed and for each ml of this mixture about
8 μΐ of cholesterol oxidase (EC 1.1.3.6) suspension (25 kU/1,
Boehringer Mannheim, No. 126934), followed by 8 μΐ of an
aqueous solution of horse radish peroxidase (EC 1.11.1.7)
(Sigma Chem. Co., Type I) 3 g/1, and 10 μΐ of aqueous 0.12 mol/1
EDTA.
The examined serum (150 μΐ) was diluted with 150 μΐ of an
aqueous solution containing 1 g/1 heparin and 0.15 mol/1 NaCl.
After mixing 30 μΐ of aqueous 0.26 mol/1 zinc acetate solution
were added, mixed well and incubated in a water bath for
about l h at 40 °C. Then the tube was cooled to room tempe-
rature (23-25 °C) in a water bath for 5 min and centrifuged
at about 3000 g for 15 min. To 100 μΐ of the supernatant
500 μΐ of the cholesterol reagent were added, incubated at
38 °C for 15-20 min and the red colour was read at 500 nm
against a blank consisting of 100 μΐ of 0.15 mol/1 NaCl in-
cubated with 500 μΐ of the reagent. When the colour was too
deep to be measured only 50 or 25 μΐ of the supernatant
diluted with 50 or 75 μΐ of 0.15 mol/1 NaCl were used and
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the results were multiplied by 2 or 4. The resulting absorbance
was multiplied by the factor 3.405 to obtain the serum lipo-
protein-X concentration in g/1. This factor was derived from
the data (absorbance χ 5.85) given in the directions (4), taking
in account the real volume of serum (45.5 μ\) applied to the
enzymatic colour reaction, the dilution factor of the reagent
(—), i. e. 100 μΐ of the supernatant instead of 5 μΐ sample
added to 500 μΐ of the enzymatic reagent, and the non-es-
terified cholesterol content of lipoprotein-X (224 g/kg).
The removal of lipoproteins other than lipoprotein-X was
checked by submitting the supernatant obtained after heparin-
Zn2+ precipitation to agar gel electrophoresis and detection with
Ca2*-dextran sulfate. No turbidity was observed on the anodic
side of the well, which indicates that anodically migrating lipo-
proteins are virtually absent. (This check is not included into
the routine procedure.) The same test was done with the
lipoprotein-X concentrate (3) used for the construction of
a calibration curve (fig. 1). No anodically migrating lipopro-
teins were detected. In this sample of lipoprotein-X concentrate
the contents of phospholipids (14.6 g/1), of non-esterified
cholesterol (5.05 g/1), and of total cholesterol (5.75 g/1)
indicated an lipoprotein-X concentration of 22 g/1.
Results and Discussion
Pooled sera from normal persons and the sera from
various disease states were investigated by this method
and the results were compared with those obtained
by turbidimetry (3) and agar gel electrophoresis
(table 1). The lipoprotein-X positive sera were ana-
lyzed several times (n) within one run and statistically
evaluated (5). The variation coefficients (CV) were in
the range of 0.61 and 4.87, the highest CV being with
the lowest lipoprotein-X levels. Two samples of sera
preserved with NaN3 (1.5 g/1) were analyzed each
day for 5 days and the means (x) of 2.32 g/1 and S. D.
of 0.054 (CV = 2.33%) and χ = 5.73 g/1, S. D. = 0.102
(CV = 1.78%) were obtained. The results calculated
with the use of the factor (3.405) agree well with those
read from the calibration curve (fig. Ϊ).
Unconjugated and conjugated bilirubins added to serum,
although inhibitory when added directly to the super-
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Fig. 1. Calibration curve
Absorbance values at 500 nm. The lipoprotein-X solution
of a known concentration (3) was added in increasing
amounts to normal pooled serum to give lipoprotein-X
levels indicated on the abscissa.
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so that the inhibitory concentration in the supernatant
was not attained even at a bilirubin concentration of
513 jumol/1 in the serum containing 2.34 g/lipoprotein-X.
Higher lipoprotein-X concentration caused higher bilirubin
in the supernatant, while serum without lipoprotein-X
yielded a supernatant with no appreciable bilirubin.
Since the determination of higher lipoprotein-X levels
required dilution of the supernatant, the inhibitory
bilirubin concentration was never reached. Ascorbate
did not inhibit when added to the analyzed serum up to
a concentration of 227 μπιοΐ/ΐ. Such high serum as-
corbate was not reported even after a large ascorbic
acid dose (6). Sodium azide and p-hydroxymercuriben-
zoate did not inhibit in the concentrations tested (i. e.
52.4 and 3.32 mmol/1, resp.).
The method is simple, it allows the lipoprotein-X to be
determined even at very low serum levels not mea-
surable by either of the previously described methods
(1) and it eliminates the need to prepare the lipopro-
tein-X solution of a known concentration (3). The
present method, like the immunoprecipitation method,
is not applicable to very strongly chylous sera of milky
appearance (2), e. g., a case with 12.6 mmol/1 trigly-
cerides and 6.92 mmol/1 cholesterol gave a slight false
absorbancy of 0.035 (which would correspond to
0.12 g/1 lipoprotein-X). This was caused by ex-
cessively increased non-lipoprotein-X lipoproteins
which were not completely precipitated with heparin-
Zn2+.
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